05 510(k) Summary

Date: March 31st, 2014

Submitted By: Esther Carbon
Manager, Global Regulatory Labeling
RTI Surgical, Inc.
11621 Research Circle
Alachua, FL 32615
Tel: 386-418-8888
Fax: 386-418-1627

Trade Name:
Bovine Pericardium Suturable Dural Graft, Tutopatch™ DM Graft, Tutoplast® Bovine Pericardium DM

Classification Name and Code:
Dura substitute (21 CFR 882.5910, product code GXQ)

Substantial Equivalence:
The proposed device is substantially equivalent to the predicate device Dura-Guard (K950956 and K982282) and Lyoplant (K970851) in intended use, material, design and function. The proposed device is substantially equivalent to the predicate device Dura-Matrix (K061487) in intended use, design and function. The proposed device is similar in design, function, materials and processing to reference devices Tutopatch™ bovine pericardium (K991296, K073097, K081538 and K091142) and similar to intended use, function, design and processing to reference device Tutoplast® Dura Mater (K910555).

Device Description:
The proposed device is composed of bovine pericardium processed through a proprietary tissue preservation and sterilization process which includes gamma irradiation. The proposed device is composed of collagenous connective tissue with three-dimensional intertwined fibers and can be fixed regardless of the direction of the device. Collagenous connective tissue with multidirectional fibers retains the mechanical strength and elasticity of the native tissue, while providing the basic structure to support replacement by new endogenous tissue. The proposed device in its unopened, undamaged package is sterile.

Indications for Use:
The device is indicated as a dura substitute for the repair of dura mater.
### Summary of Technological Characteristics:
This proposed device is composed of non-crosslinked bovine pericardium that has been processed, terminally sterilized and stored dehydrated. The device has the same technological characteristics as the predicate device in material, design, intended use and function as listed in the table below:

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Proposed Device</th>
<th>Predicate Device, Dura-Guard (K950956 and K982282)</th>
<th>Predicate Device, DuraMatrix (K061487)</th>
<th>Predicate Device, Lyoplant (K970851)</th>
<th>Reference Device, Tutopatch (K991296, K081538, K091142)</th>
<th>Reference Device, Tutodent (K073097)</th>
<th>Reference Device, Tutoplast processed human dura mater (K910555)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intended Use</td>
<td>Dura substitute</td>
<td>SAME</td>
<td>SAME</td>
<td>SAME</td>
<td>Surgical mesh</td>
<td>Barrier, Animal Source, Intraoral</td>
<td>SAME</td>
</tr>
<tr>
<td>Material</td>
<td>Bovine pericardium</td>
<td>SAME</td>
<td>Bovine collagen</td>
<td>Collagen from bovine pericardium</td>
<td>SAME</td>
<td>SAME</td>
<td>Human dura</td>
</tr>
<tr>
<td>Design</td>
<td>Terminally sterilized sheets in various sizes</td>
<td>Aseptically processed sheets in various sizes</td>
<td>Resorbable, suturable membrane</td>
<td>Absorbable, suturable membrane</td>
<td>SAME</td>
<td>SAME</td>
<td>SAME</td>
</tr>
<tr>
<td>Function</td>
<td>Dura substitute</td>
<td>SAME</td>
<td>SAME</td>
<td>SAME</td>
<td>Scaffold for soft tissue repair</td>
<td>Scaffold for soft tissue repair</td>
<td>SAME</td>
</tr>
<tr>
<td>Processing</td>
<td>Proprietary tissue sterilization process</td>
<td>Apex processing</td>
<td>Proprietary processing</td>
<td>Proprietary processing</td>
<td>SAME</td>
<td>SAME</td>
<td>SAME</td>
</tr>
<tr>
<td>Chemical composition</td>
<td></td>
<td>Not applicable to these devices</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy Source</td>
<td></td>
<td>Not applicable to these devices</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Performance Data Supporting Substantial Equivalence Determination:
The proposed device is equivalent to the predicate devices in intended use, material, design, and function. The biomechanical properties of the proposed and predicate devices were evaluated in a series of in vitro tests and implantation in an animal model. Burst strength, uniaxial strength and suture pullout strength were substantially equivalent for the proposed and predicate devices. The table below summarizes the testing used to determine substantial equivalence of the proposed device.

<table>
<thead>
<tr>
<th>Test</th>
<th>Results</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytotoxicity – Inhibition of Cell Growth Assay</td>
<td>No leachable materials were released in cytotoxic concentrations from the device. The proposed device is non-cytotoxic.</td>
<td>Substantially equivalent</td>
</tr>
<tr>
<td>Suture Pull out (N)</td>
<td>The proposed device suture pull-out max load is comparable to the DuraMatrix predicate device.</td>
<td>Substantially equivalent</td>
</tr>
<tr>
<td>Burst Strength (N)</td>
<td>The proposed device burst strength is greater than the DuraMatrix predicate device.</td>
<td>Substantially equivalent</td>
</tr>
<tr>
<td>Shrink temperature (°C)</td>
<td>The shrink temperature of the proposed device is comparable to the Lyoplant predicate device.</td>
<td>Substantially equivalent</td>
</tr>
<tr>
<td>Max Load (N)</td>
<td>The maximum load at failure of the proposed device is comparable to the DuraMatrix predicate device.</td>
<td>Substantially equivalent</td>
</tr>
</tbody>
</table>

Pyrogenicity of the device was evaluated using the Limulus Amoeocyte Lysate (LAL) assay on the final sterilized device. The device did not elicit a response. All device lots will be tested to ensure the endotoxin level is <2.15 EU per device.

The functional properties of the proposed and predicate device were evaluated in a pre-clinical implantation study and the proposed device performed as well as a similar dura substitute. Clinical and gross pathology, cerebrospinal fluid leakage and the local effects of implantation were assessed and results demonstrate the proposed and predicate devices are substantially equivalent. The proposed device was increasingly resorbed. At the end time point the proposed device demonstrated moderate resorption and marked integration.

Clinical evaluation of the proposed device confirms the clinical substantial equivalence to the predicate devices. Sabatino et. al. (2014)¹ present the results of a prospective cohort study which compared the clinical outcomes from duraplasty using autologous galea-pericranium and Tutopatch (the proposed device as marketed in the European market). The study evaluated postoperative results (with a minimum follow-up of 12 months), ease of use and procedure costs. The proposed device performed adequately with no evidence of adverse health effects. Filipi et. al. (2000)² present a retrospective evaluation that summarized the outcomes for 32 patients who received Tutoplast bovine pericardium dural grafts (proposed device as marketed in ex-US countries) as part of a variety of neurosurgical procedures. The proposed device was easily sutured with standard suture material and formed a watertight seal. The proposed device provided “excellent material implantation characteristics and favorable clinical outcome”³ and is recommended as a safe and suitable material for duraplasty. Filipi et. al. concluded, “these results confirm the excellent suitability of Tutoplast bovine pericardium for dural substitution”. Results from in vitro, animal studies and clinical evaluation demonstrate that the proposed device is substantially equivalent to the predicate devices for use as a dura substitute.

March 31, 2014

RTI Surgical, Inc.
Ms. Esther Carbon
Manager, Global Regulatory Labeling
11621 Research Cir.
Alachua, FL 32615

Re: K132850
   Trade/Device Name: Bovine Pericardium Suturable Dural Graft, Tutopatch™ DM Graft, or Tutoplast® D Bovine Pericardium DM
   Regulation Number: 21 CFR 882.5910
   Regulation Name: Dura Substitute
   Regulatory Class: Class II
   Product Code: GXQ
   Dated: February 24, 2014
   Received: February 26, 2014

Dear Ms. Esther Carbon:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply
with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Joyce M. Whang -S

for Carlos L. Peña, PhD, MS
Director
Division of Neurological
and Physical Medicine Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
510(k) Number (if known)
K132850

Device Name
- Bovine Pericardium Suturable Dural Graft
- Tutoplast® Bovine Pericardium DM
- Tutopatch™ DM Graft

Indications for Use (Describe)

The device is indicated as a dura substitute for the repair of dura mater.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)  ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

Joyce M. Whang -S
This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

*An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.*